BioLineRx (NASDAQ:BLRX – Get Rating) posted its quarterly earnings results on Wednesday. The biotechnology company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01), Zacks reports. During the same quarter last year, the business earned ($0.10) earnings per share.
BioLineRx Stock Down 5.9 %
BioLineRx stock traded down $0.09 during midday trading on Friday, hitting $1.46. 459,943 shares of the stock were exchanged, compared to its average volume of 406,691. BioLineRx has a 52-week low of $0.55 and a 52-week high of $1.98. The stock has a market capitalization of $89.78 million, a price-to-earnings ratio of -2.65 and a beta of 1.89. The business’s 50-day moving average price is $1.12 and its 200-day moving average price is $0.81. The company has a quick ratio of 4.87, a current ratio of 4.87 and a debt-to-equity ratio of 0.17.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Envestnet Asset Management Inc. purchased a new position in BioLineRx in the first quarter valued at about $88,000. Renaissance Technologies LLC boosted its stake in BioLineRx by 278.0% in the fourth quarter. Renaissance Technologies LLC now owns 257,900 shares of the biotechnology company’s stock valued at $152,000 after acquiring an additional 189,678 shares during the last quarter. LPL Financial LLC boosted its stake in BioLineRx by 152.7% in the fourth quarter. LPL Financial LLC now owns 117,710 shares of the biotechnology company’s stock valued at $69,000 after acquiring an additional 71,134 shares during the last quarter. Finally, Atria Wealth Solutions Inc. purchased a new position in BioLineRx in the first quarter valued at about $178,000. 18.15% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
BioLineRx Ltd. is a clinical stage biopharmaceutical company, which engages in the research and development of treatments that focus on cancer. Its product pipeline includes Motaxafortide (BL-8040), which is used for stem-cell mobilization, solid tumors, and acute myeloid lukemia; and AGI-134, which is an immunotherapy treatment used for multiple solid tumors.
- Get a free copy of the StockNews.com research report on BioLineRx (BLRX)
- Big Lots Becomes A Stomach Churning Value Play
- The Melt-Up In Marvell Is On; But Don’t Chase It Higher
- Is Apple a Growth Stock or a Value Stock?
- Costco’s Earnings Call Reassure Economists, Recession Cancelled
- Hot Inflation, What It Means For The Summer Rally
Receive News & Ratings for BioLineRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx and related companies with MarketBeat.com's FREE daily email newsletter.